Purity: Teneur ≥98,0 % sur base sèche par HPLC (ou selon la monographie pharmacopéique), conforme à la spécification de grade pharmaceutique/technique.
Loss on Drying: Perte à la dessiccation ≤0,5 % p/p, déterminée selon la méthode pharmacopéique (USP <731> / Ph. Eur. 2.2.32).
Residual Solvents: Solvants résiduels contrôlés dans les limites ICH Q3C pour la classe de solvant concernée.
Profil d'impuretés: Toute impureté individuelle non spécifiée ≤0,10 % ; impuretés totales ≤0,50 %, conformément aux directives ICH Q3A/B.

Autres informations

Description supplémentaire:

Building on strong chemical development and manufacturing capabilities, Laurus Labs has built an in-house range of APIs and related intermediates, targeting chemistries where it can add real value—pairing innovation with efficiency through cost-effective processes and matching capacity investment for supply reliability. Laurus ranks among the world's leading suppliers of anti-retroviral APIs and intermediates, with low-cost technologies intended to widen medicine access globally. The company partners closely with innovators, global health organizations, and providers to meet cost-reduction goals without compromising quality, and its facilities for handling highly potent materials at development and commercial scale support oncology as a core focus area.